Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights

doi:10.4254/wjh.v7.i14.1834

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8330)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

596

WORD

239

HTML

5026

Figures (1-2)

206

Sum=6067

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

929

Download

1334

Sum=2263

Jul 18, 2015 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Jul 18, 2015; 7(14): 1834-1842
Published online Jul 18, 2015. doi: 10.4254/wjh.v7.i14.1834

Open in New Tab Full Size Figure Download Figure

Figure 1 Hepatocellular cancer therapeutic methods. HCC: Hepatocellular cancer; TACE: Transarterial chemoembolization; RF: Radiofrequency.

Open in New Tab Full Size Figure Download Figure

Figure 2 Changes of circulating markers and immune parameters associated with good hepatocellular cancer response after radiofrequency or transarterial chemoembolization. HCC: Hepatocellular cancer; TACE: Transarterial chemoembolization; RF: Radiofrequency; AFP: Alpha-fetoprotein; DCP: Des-gamma-carboxy prothrombin; VEGF: Vascular endothelial growth factor; HIF-1a: Hypoxia inducible factor-1a; NLR: Neutrophil-to-lymphocyte ratio; sRAGE: Soluble receptor of advanced glycation end products; HSP70: Heat shock protein 70; OPN: Osteopontin; LDH: Lactate dehydrogenase.

Citation: Tampaki M, Doumba PP, Deutsch M, Koskinas J. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World J Hepatol 2015; 7(14): 1834-1842
URL: https://www.wjgnet.com/1948-5182/full/v7/i14/1834.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i14.1834